South Korea
· Delayed Price · Currency is KRW Abpro Bio Statistics
Total Valuation
Abpro Bio has a market cap or net worth of KRW 136.08 billion. The enterprise value is 147.24 billion.
| Market Cap | 136.08B |
| Enterprise Value | 147.24B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Abpro Bio has 284.69 million shares outstanding. The number of shares has increased by 3.17% in one year.
| Shares Outstanding | 284.69M |
| Shares Change (YoY) | +3.17% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 3.21% |
| Owned by Institutions (%) | 0.45% |
| Float | 264.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.28 |
| PB Ratio | 1.11 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.30 |
| EV / Sales | 7.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.48 |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.98 |
| Quick Ratio | 0.46 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.74 |
| Interest Coverage | -4.95 |
Financial Efficiency
Return on equity (ROE) is -15.59% and return on invested capital (ROIC) is -5.44%.
| Return on Equity (ROE) | -15.59% |
| Return on Assets (ROA) | -5.10% |
| Return on Capital (ROIC) | -5.44% |
| Revenue Per Employee | 364.40M |
| Profits Per Employee | -395.33M |
| Employee Count | 51 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 0.96 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.86% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -10.86% |
| 50-Day Moving Average | 464.48 |
| 200-Day Moving Average | 511.65 |
| Relative Strength Index (RSI) | 56.45 |
| Average Volume (20 Days) | 1,635,867 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Abpro Bio had revenue of KRW 18.58 billion and -20.16 billion in losses. Loss per share was -71.27.
| Revenue | 18.58B |
| Gross Profit | -696.17M |
| Operating Income | -12.69B |
| Pretax Income | -20.17B |
| Net Income | -20.16B |
| EBITDA | -10.80B |
| EBIT | -12.69B |
| Loss Per Share | -71.27 |
Balance Sheet
The company has 7.88 billion in cash and 19.04 billion in debt, giving a net cash position of -11.16 billion or -39.21 per share.
| Cash & Cash Equivalents | 7.88B |
| Total Debt | 19.04B |
| Net Cash | -11.16B |
| Net Cash Per Share | -39.21 |
| Equity (Book Value) | 122.67B |
| Book Value Per Share | 430.88 |
| Working Capital | 24.13B |
Cash Flow
In the last 12 months, operating cash flow was -4.66 billion and capital expenditures -6.26 billion, giving a free cash flow of -10.93 billion.
| Operating Cash Flow | -4.66B |
| Capital Expenditures | -6.26B |
| Free Cash Flow | -10.93B |
| FCF Per Share | -38.38 |
Margins
Gross margin is -3.75%, with operating and profit margins of -68.29% and -108.49%.
| Gross Margin | -3.75% |
| Operating Margin | -68.29% |
| Pretax Margin | -108.55% |
| Profit Margin | -108.49% |
| EBITDA Margin | -58.10% |
| EBIT Margin | -68.29% |
| FCF Margin | -58.79% |
Dividends & Yields
Abpro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.17% |
| Shareholder Yield | -3.17% |
| Earnings Yield | -14.91% |
| FCF Yield | -8.03% |
Stock Splits
The last stock split was on August 21, 2017. It was a reverse split with a ratio of 0.2.
| Last Split Date | Aug 21, 2017 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Abpro Bio has an Altman Z-Score of 1.84. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | n/a |